Malaysia's Health Ministry has now disclosed the full tally from a two-year enforcement push against unregistered GLP-1 weight-loss products: 19 raids, and RM405,170 worth of medicines pulled off the market. The figures were given to parliament on 2 November by Health Minister Datuk Seri Dr Dzulkefly Ahmad.
What Happened
Answering an oral question in the Dewan Rakyat, Dzulkefly broke the enforcement record into two parts.
Twelve raids between 2025 and September 2026 targeted retatrutide, an experimental triple-agonist that has never been approved by any regulator anywhere in the world. Those operations recovered 697 units worth RM341,000.
A further seven raids targeted Ozempic and other semaglutide products sold without authorisation, recovering 62 units worth RM64,170.
"It is not yet in our formulary," Dzulkefly said of retatrutide. The ministry stated in August that the compound remains an investigational medicine in Phase 3 trials with no marketing approval from any regulator globally.
The question came from Datuk Seri Dr Zaliha Mustafa (PH-Sekijang), who noted that GLP-1 products are heavily promoted by influencers on TikTok while being sold online with little oversight — and asked how many arrests had followed and what firmer strategy the ministry would adopt.
Who Is Affected
Three groups sit in the enforcement zone.
- Malaysian consumers buying injectable GLP-1s from social commerce listings, where cold-chain and product authenticity cannot be verified.
- Legitimate clinics and pharmacies that dispense registered products and now compete against unregistered imports at a fraction of the price.
- Cross-border sellers, including accounts operating from outside Malaysia, which the ministry says it monitors through e-commerce platform cooperation.
Retatrutide is the sharpest edge of the problem. Unlike compounded or imported semaglutide, it has no approved version to compare against, so buyers have no reference point for identity, purity, or sterility.
Timeline
- 2025 through September 2026 — 12 raids on retatrutide sellers, 7 on unauthorised semaglutide.
- August 2026 — ministry publicly confirms retatrutide is investigational and unapproved worldwide.
- 2 November 2026 — full seizure totals tabled in parliament; minister commits to continued e-commerce monitoring.
What This Means for Researchers
For anyone studying GLP-1 receptor agonists in a research context, the Malaysian numbers matter for two reasons.
First, they confirm that investigational compounds are circulating in consumer supply chains before approval, which makes sourcing documentation — not price — the primary risk control. Second, they show enforcement is now measured in units and ringgit rather than warnings, meaning sellers face criminal exposure rather than takedown notices.
The ministry's enforcement toolkit is worth noting: advertisement screening, removal of listings from e-commerce platforms, investigation of complaints, and raids under the Pharmacy Enforcement Division, alongside the Tolak Ubat Tidak Sah (TOBaTS) public awareness campaign.
How to Verify Your Peptides
Retatrutide has no approved reference standard, so third-party testing is the only way to know what a vial actually contains. Identity and purity results should come from an independent laboratory using HPLC for purity and LC-MS for molecular identity, with fill weight measured separately.
- How peptide testing works
- HPLC vs LC-MS: what each method proves
- Identity, purity and fill weight explained
Safe Alternatives
If you are working with compounds that have documented regulatory status rather than investigational ones, start from the approved-product side:
- Retatrutide compound profile — investigational status and trial data
- Semaglutide compound profile — approved GLP-1 reference
- Verified vendor directory — suppliers with published testing documentation
Sources
Regulatory announcements, Malaysia Ministry of Health (Dewan Rakyat session, 2 November 2026); ministry statements on retatrutide's investigational status, August 2026.